<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289780</url>
  </required_header>
  <id_info>
    <org_study_id>BDX-00146</org_study_id>
    <nct_id>NCT03289780</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodesix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodesix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information about how a doctor uses the results of
      the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients.
      Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes
      may help doctors to better treat NSCLC in the future. This study will also look to establish
      whether new investigational tests can help better predict the effectiveness of certain
      medications for certain patients. These new investigational tests are only for research
      purposes at this time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this observational study is to assess the physician's clinical
      practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are
      epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR mutational
      status. This study will also attempt to further validate that VeriStrat test results stratify
      subjects by clinical outcomes in the real world, uncontrolled clinical setting while
      exploring whether certain therapeutic approaches may yield opportunities for further study.

      Predictive tests that aid physician therapeutic decision making are critical for optimizing
      subject outcomes while minimizing toxicity and associated treatment costs. This study will
      provide data for the validation of immunotherapy tests currently being developed.
      Immunotherapy mechanisms are dependent upon the interactions between the tumor, tumor
      microenvironment, and the patient immune system. As such, a successful predictive test will
      reflect the complex interplay between tumor and host. The multivariate tests from Biodesix
      have the advantage of being able to assess this complex biology.

      The information gained from this research will not only guide the adoption of the VeriStrat
      test and inform medical decision making, including treatment choice, but will allow the
      validation of additional mass-spectrometry-based proteomic tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician Treatment Patterns Description</measure>
    <time_frame>18 months</time_frame>
    <description>1. Physician Treatment patterns Description: To describe physician treatment patterns pre and post-veriStrat testing. Describe the impact of the VeriStrat test results on treatment decisions, including but not limited to: percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat good and those classified as VeriStrat Poor. Change in percentage of patients receiving systemic therapy or supportive therapies only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunotherapy Stratification by Overall Survival</measure>
    <time_frame>18 month</time_frame>
    <description>To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunotherapy Stratification by Progression-Free Survival</measure>
    <time_frame>18 months</time_frame>
    <description>To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VeriStrat Poor vs. Good Outcomes</measure>
    <time_frame>18 months</time_frame>
    <description>To compare progression free survival (PFS) and overall survival (OS) outcomes between those classified as VeriStrat-Poor and VeriStrat-Good.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platinum-based therapy outcomes in VeriStrat Poor vs. Good subjects.</measure>
    <time_frame>18 months</time_frame>
    <description>To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with platinum-based therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunotherapy outcomes in VeriStrat Poor vs. Good subjects.</measure>
    <time_frame>18 months</time_frame>
    <description>To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with immunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemcitabine outcomes in VeriStrat Poor vs. Good Subjects</measure>
    <time_frame>18 months</time_frame>
    <description>To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with gemcitabine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VeriStrat label changes over time.</measure>
    <time_frame>18 months</time_frame>
    <description>To compare the longitudinal changes in VeriStrat classification over the course of the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of Immunotherapy tests ability to stratify subjects based on treatment.</measure>
    <time_frame>18 months</time_frame>
    <description>To compare progression free survival (PFS) and overall survival (OS) outcomes in patients as stratified by the immunotherapy test(s) treated with chemotherapy or targeted therapies.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between the VeriStrat test and Immunotherapy tests.</measure>
    <time_frame>18 months</time_frame>
    <description>To observe the correlation between VeriStrat classification and immunotherapy test(s) classification at baseline and longitudinally.</description>
  </other_outcome>
  <other_outcome>
    <measure>Longitudinal changes in Immunotherapy tests.</measure>
    <time_frame>18 months</time_frame>
    <description>To describe the longitudinal changes in immunotherapy test classification over the course of the study.</description>
  </other_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any Subject with Non-Small Cell Lung Cancer (NSCLC) at all stages with any histology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be 18 years of age or older at time of signing informed consent form
             (ICF).

          2. A diagnosis of NSCLC.

          3. EGFR mutation status wildtype or unknown.

          4. Subject is willing to provide serum samples for VeriStrat testing.

          5. For subjects with UNKNOWN EGFR status only: The subject must be willing to provide
             plasma samples for GeneStrat testing.

          6. Subject is willing to provide serum samples for research, understanding that no test
             results will be made available either to the subject or the treating physician.

          7. If subject has had prior treatment for local disease, disease progression was
             documented and treatment was completed prior to VeriStrat testing.

          8. Subject is able to read and understand the ICF, and agrees to comply with study
             procedures and requirements.

        Exclusion Criteria:

          1. History of prior malignancy within 2 years of signing ICF (except for adequately
             treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix,
             superficial bladder cancer, or early stage prostate cancer, without evidence of
             recurrence).

          2. Subject's ability to understand the requirements of the protocol or to provide
             informed consent is impaired or subject is unwilling to comply with the protocol
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Traylor, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biodesix, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niki Givens, B.S.</last_name>
    <phone>720-495-1583</phone>
    <email>niki.givens@biodesix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alix Arnaud, M.S</last_name>
    <phone>720-509-8845</phone>
    <email>alix.arnaud@biodesix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Specialties, PC; Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lewis &amp; Faye Manderson Cancer Center at DCH Regional Medical Center</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Daniel, RN</last_name>
      <phone>205-343-8331</phone>
      <email>danielle.daniel@dchsystem.com</email>
    </contact>
    <investigator>
      <last_name>John Dubay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Noble, RN</last_name>
      <phone>479-878-5447</phone>
      <email>knoble@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Eric Schaefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernards Cancer Center Hematology / Oncology</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Moon, RN</last_name>
      <phone>870-910-7723</phone>
      <email>amber.moon@cloptonclinic.com</email>
    </contact>
    <investigator>
      <last_name>Mazen Khalil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aamer Farooq, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Medical Oncology Consultants</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Popal, RN</last_name>
      <phone>925-734-8130</phone>
      <phone_ext>157</phone_ext>
      <email>mpopal@vmoc.com</email>
    </contact>
    <investigator>
      <last_name>Rishi Sawhney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Johnson, Phrm D</last_name>
      <phone>860-886-8362</phone>
      <email>drsusanjohnson@cox.net</email>
    </contact>
    <investigator>
      <last_name>Dinesh Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital -Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubrey Gonzalez, RN</last_name>
      <phone>561-955-4519</phone>
      <email>agonzalez@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Edgaurdo Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake City Cancer Care, LLC</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanette Strosser, RN</last_name>
      <phone>386-755-1655</phone>
      <phone_ext>6214</phone_ext>
      <email>SLStrosser@ccofnf.com</email>
    </contact>
    <investigator>
      <last_name>Waseemullah Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vernon Montoya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uma Iyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Eastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Finger, BSHP</last_name>
      <phone>770-400-6077</phone>
      <email>elizabeth.Finger@ctca-hope.com</email>
    </contact>
    <contact_backup>
      <last_name>Mittie Mitchell, RN</last_name>
      <phone>770-400-7194</phone>
      <email>mittie.mitchell@ctca-hope.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Thompson-Rich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Care</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Powell, RN</last_name>
      <phone>912-651-5771</phone>
      <email>spowell@summitcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Georgia Medical Center</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Zipperer, RN</last_name>
      <phone>229-259-4698</phone>
      <email>julie.zipperer@sgmc.org</email>
    </contact>
    <investigator>
      <last_name>Eric Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Stoner, RN</last_name>
      <phone>317-528-7060</phone>
      <email>cynthia.stoner@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Nadeem Ikhlaque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponchartrain Cancer Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McKean, RN</last_name>
      <phone>985-888-1523</phone>
      <email>chelsea@pcclouisiana.com</email>
    </contact>
    <investigator>
      <last_name>David Oubre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center - Hematology and Oncology Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Sommerford, RN</last_name>
      <phone>662-377-4550</phone>
      <email>aqsummerford@nmhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Brian Donner, RN</last_name>
      <phone>662-377-4624</phone>
      <email>BCDonner@nmhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Tan Jiahuai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essex Oncology</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Johnstone</last_name>
      <phone>973-751-8880</phone>
      <phone_ext>272</phone_ext>
      <email>trials@essexoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Orsini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Said Saleh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hemalatha Vasireddy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sita Yerramalli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Conti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Harrison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats, RN</last_name>
      <phone>516-488-2918</phone>
      <phone_ext>121</phone_ext>
      <email>ckats@researchcra.com</email>
    </contact>
    <investigator>
      <last_name>Morton Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Apurv Agrawal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Girish Amin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Kay Barton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noshir DaCosta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Decter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jayne Pavlak-Schenk, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Fischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Gold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Goldberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Halaas, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Jablonski, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randi Joy Katz, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raghu Kunamneni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Lipera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abraham Mittelman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Nahum, DO, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahid Nawaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley Ostrow, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Pasmantier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Rubin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Samuel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Theodorakis, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Vacirca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ethan Wasserman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Cooke, RN</last_name>
      <phone>919-587-9077</phone>
      <email>ecooke@cancersmoc.com</email>
    </contact>
    <investigator>
      <last_name>James Atkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center - East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Walker, RN</last_name>
      <phone>252-744-1888</phone>
      <email>walkerkai16@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates - Mercy Medical Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Edwards, RN</last_name>
      <phone>330-489-1274</phone>
      <email>joan.edwards@cantonmercy.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Haut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-County Hematology &amp; Oncology Associates</name>
      <address>
        <city>Massillon</city>
        <state>Ohio</state>
        <zip>44646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Edwards, RN</last_name>
      <phone>330-489-1274</phone>
      <email>joan.edwards@cantonmercy.org</email>
    </contact>
    <investigator>
      <last_name>Nagaprasad Nagajothi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan McCartney, RN</last_name>
      <phone>717-334-4033</phone>
      <email>megan@gettysburgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Satish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Lowery, RN</last_name>
      <phone>864-603-6214</phone>
      <email>amanda_lowery@bshi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kinloch, RN</last_name>
      <phone>817-543-4645</phone>
      <email>andreakinloch@texashealth.org</email>
    </contact>
    <investigator>
      <last_name>Barry Firstenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JPS Health Network, JPS Center for Cancer Care</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Caliman, RN</last_name>
      <phone>817-702-6776</phone>
      <email>ccaliman@jpshealth.org</email>
    </contact>
    <investigator>
      <last_name>Jordan Christopher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Halstead, LVN</last_name>
      <phone>817-341-5414</phone>
      <email>bhalstead@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Ray D Page, DO, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital and Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deedra Preece, RN</last_name>
      <phone>254-724-2111</phone>
      <email>dedra.preece@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Alan Gowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Moore, RN</last_name>
      <phone>804-288-7159</phone>
      <email>smoore@vacancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Neff, RN</last_name>
      <phone>804-287-3000</phone>
      <phone_ext>1263</phone_ext>
      <email>saneff@vacancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Sandefur, RN</last_name>
      <phone>253-428-8712</phone>
      <email>ssandefur@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biodesix.com</url>
    <description>Sponsor Website</description>
  </link>
  <reference>
    <citation>Akerley WL, Arnaud AM, Reddy B, Page RD. Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin. 2017 Jun;33(6):1091-1097. doi: 10.1080/03007995.2017.1301903. Epub 2017 Mar 16.</citation>
    <PMID>28277859</PMID>
  </reference>
  <reference>
    <citation>Grossi F, Rijavec E, Genova C, Barletta G, Biello F, Maggioni C, Burrafato G, Sini C, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br J Cancer. 2017 Jan 3;116(1):36-43. doi: 10.1038/bjc.2016.387. Epub 2016 Nov 29.</citation>
    <PMID>27898657</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

